Adalimumab

May 24, 2017

Miraca’s InformTx Treatment Response Platform for IBD Now Includes Testing for Inflectra

News

Miraca Life Sciences‘ InformTx testing helps doctors assess the response of patients with inflammatory bowel disease (IBD) to certain drug treatments. The company has now expanded its therapeutic drug monitoring ... Read more

September 27, 2016

U.S. FDA Approves Biosimilar Amjevita for Multiple Inflammatory Diseases

News

The Division of Drug Information at the U.S. Food and Drug Administration (FDA) has announced its approval of Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for the treatment of multiple ... Read more

May 26, 2016May 26, 2016

AbbVie Showcases IBD Therapies at Digestive Disease Week Annual Meeting

Crohn's Disease, IBD News, News, Ulcerative colitis

North Chicago, Illinois based multinational biopharmaceutical company AbbVie presented 13 abstracts at the Digestive Disease Week (DDW) Annual Meeting held May 21-24, 2016, at San Diego, California. Abstracts presented addressed ... Read more

May 2, 2016May 2, 2016

Certain Drug Therapies for Pregnant Women with IBD Can Have Impact on Newborns

News

Infants born to women who were treated with antibodies against tumor necrosis factor alpha (TNF alpha) during pregnancy have detectable levels of antibodies until 12 months of age, according to the results ... Read more

November 20, 2015November 20, 2015

Successful Remission in Ulcerative Colitis Patients Achieved Using Combination Therapy

News

In a new study entitled “Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis,” a team of researchers investigated if a combined ... Read more

February 20, 2015February 20, 2015

Oncobiologics Announces Successful Clinical Trial for IBD Treatment

IBD News, News

Biopharmaceutical company Oncobiologics, Inc. recently announced that its product ONS-3010, an adalimumab (Humira®) biosimilar candidate, has met the primary endpoints in its first clinical trial. ONS-3010 was developed as a biosimilar of adalimumab, ... Read more

January 2, 2015January 2, 2015

Torrent Pharma and Reliance Life Sciences Partner to Market IBD Biosimilars

IBD News, News

Torrent Pharmaceuticals Ltd. has signed a licensing agreement with Reliance Life Sciences for the marketing of three biosimilar products in India. The two companies are planning to market the biosimilars adalimumab, a treatment for ... Read more

December 16, 2014December 16, 2014

UK Patients with Moderately to Severely Active UC Gain Access to New Drugs

News, Ulcerative colitis

Patients with moderately to severely active ulcerative colitis, residing in the United Kingdom, now have access to several new drugs thanks to the Final Appraisal Document (FAD) from the National Institute ... Read more

December 3, 2014September 28, 2016

Humira Biosimilar Drug Accepted to Conduct Clinical Trial in UK for Crohn’s, Other Autoimmune Diseases

News

Cambridge, Massachusetts-based biotechnology company, Momenta Pharmaceuticals, Inc., has just announced the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted the company’s Clinical Trial Application (CTA) for a study ... Read more

November 5, 2014November 5, 2014

IBD Drug Entyvio By Takeda Pharmaceuticals Is Not Proved According to IQWiG

News

In an evaluation in accordance with the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) recently assessed whether ... Read more